SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 424B5:
[]
SVA [SINOVAC BIOTECH] 6-K: (Original Filing)
[Sinovac Schedules 2014 Annual Meeting of Shareholders BEIJING, July 14, 2014 -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that it will hold its 2014 Annual Meeting of Shareholders on Wednesday, August 27, 2014 at 9:00 a.m. Beijing Time. The meeting will be held at No. 39 Shangdi Xi Road, Haidian District,] [July 15, 2014 Dear Shareholder: You are cordially invited to attend the 2014 annual meeting of shareholders of Sinovac Biotech Ltd. to be held on August 27, 2014, at 9:00 A.M. Beijing time, at No. 39 Shangdi Xi Road, Haidian District, Beijing 100085, People’s Republic of China. At this year’s annual meeting, you will be asked to: · approve the] []
SVA [SINOVAC BIOTECH] 6-K: Sinovac Schedules 2014 Annual Meeting of Shareholders BEIJING,
[Sinovac Schedules 2014 Annual Meeting of Shareholders BEIJING, July 14, 2014 -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that it will hold its 2014 Annual Meeting of Shareholders on Wednesday, August 27, 2014 at 9:00 a.m. Beijing Time. The meeting will be held at No. 39 Shangdi Xi Road, Haidian District,] [July 15, 2014 Dear Shareholder: You are cordially invited to attend the 2014 annual meeting of shareholders of Sinovac Biotech Ltd. to be held on August 27, 2014, at 9:00 A.M. Beijing time, at No. 39 Shangdi Xi Road, Haidian District, Beijing 100085, People’s Republic of China. At this year’s annual meeting, you will be asked to: · approve the] []
SVA [SINOVAC BIOTECH] 6-K: (Original Filing)
[Sinovac Announces Favorable Reduction in Value Added Tax Rate BEIJING, June 25, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that the value added tax (or "VAT") rate applied to the sales of Sinovac's vaccine products will be reduced to 3% from the current rate of 6%, according to a] []
SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 8-K: (Original Filing)
[July 14, 2014 STRICTLY CONFIDENTIAL Weibing Lu Chairman of the Board Skystar Bio-Pharmaceutical Company 4/F Building B, Chuangye Square, No. 48 Keji Road Gaoxin District, Xi’an Province, P.R. China Dear Chairman Lu: Agreement Company Wainwright Offering Securities This letter agreement (this “ Compensation; Reimbursement Closing A. Cash Fee 1. 2. 430 Park Avenue | New York, New York 10022 |] [skystar bio-pharmaceutical company Holder Initial Exercise Date Termination Date Company Section 1 Definitions Purchase Agreement Section 2 Exercise 1 Exercise Price $6.25 Exercise Price b) Cashless Exercise c) VWAP “ 2 Mechanics of Exercise d) DWAC i. ii. Rescission Rights iii. 3 Buy-In iv. No Fractional Shares or Scrip v. 4 Charges, Taxes and Expenses provided however vi. Closing of] [July 16, 2014 Skystar Bio-Pharmaceutical Company 4/F, Building B, Chuangye Square, No. 48 Keji Rd Gaoxin District, Xi’an, Shaanxi Province, P.R. China Ladies and Gentlemen: Skystar Bio-Pharmaceutical Company In connection with the issuance by In connection with this opinion letter, we have examined and relied upon copies of the following documents, together with such other documents as we deemed necessary] [SECURITIES PURCHASE AGREEMENT Agreement Company Purchaser Purchasers This Securities Purchase Agreement (this “ Securities Act NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows: ARTICLE I. Definitions 1.1 Acquiring Person “ Action “] []
WX [WuXi PharmaTech (Cayman)] 6-K: Form 6-K TABLE OF CONTENTS Page 3 4
[Form 6-K TABLE OF CONTENTS Page 3 4 2 WuXi PharmaTech (Cayman) Inc. Edward Hu Chief Financial Officer 3]
WX [WuXi PharmaTech (Cayman)] 6-K: (Original Filing)
[Form 6-K TABLE OF CONTENTS Page 3 4 2 WuXi PharmaTech (Cayman) Inc. Edward Hu Chief Financial Officer 3]
TPI [TIANYIN PHARMACEUTICAL] 8-K/A: (Original Filing)
[CURRENT REPORT FOR ISSUERS SUBJECT TO THE Amendment No. 3 to FORM 8-K CURRENT REPORT July 3, 2014 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction of incorporation) (IRS Employer Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041]
TPI [TIANYIN PHARMACEUTICAL] 8-K/A: CURRENT REPORT FOR ISSUERS SUBJECT TO THE Amendment
[CURRENT REPORT FOR ISSUERS SUBJECT TO THE Amendment No. 3 to FORM 8-K CURRENT REPORT July 3, 2014 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction of incorporation) (IRS Employer Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041]
SVA [SINOVAC BIOTECH] 6-K: (Original Filing)
[Sinovac Enters Technology Transfer Agreement with Intravacc to Develop and Commercialize Sabin Inactivated Polio Vaccine (sIPV) -- Collaborating with World Health Organization and Intravacc to Develop sIPV in line with mission to secure a lasting polio-free world, free of all paralytic polio disease Sinovac Enters Technology Transfer Agreement with Intravacc to Develop and Commercialize Sabin Inactivated Polio Vaccine (sIPV) Collaborating] [Sinovac to Host Conference Call to Report First Quarter 2014 Unaudited Financial Results BEIJING, May 12, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the first quarter ended March 31, 2014, after market closes on Wednesday, May 21, 2014 EDT. The Company] [Sinovac Reports Unaudited First Quarter 2014 Financial Results -- -Conference call scheduled for Thursday, May 22, 2014 at 8:00 AM EDT Sinovac Reports Unaudited First Quarter 2014 Financial Results - Conference call scheduled for Thursday, May 22, 2014 at 8:00 AM EDT - BEIJING, May 21, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products] []
